[Skip to Content]
[Skip to Content Landing]
Article
July 1986

Hypoprothrombinemia in Patients With Cancer Receiving Cefoperazone and Mezlocillin

Author Affiliations

From the Section of Infectious Diseases, Department of Internal Medicine, M. D. Anderson Hospital (Drs Jones, Rolston, Fainstein, and Bodey), and the Division of Hematology-Oncology, Department of Internal Medicine, University of Texas Health Science Center (Dr Strother), Houston. Drs Jones and Strother are now with the Department of Medicine, Mt Sinai Medical Center, Milwaukee.

Arch Intern Med. 1986;146(7):1397-1399. doi:10.1001/archinte.1986.00360190183025
Abstract

• Forty-one patients with cancer who were receiving cefoperazone sodium plus mezlocillin sodium were prospectively followed up for the development of abnormal bleeding or hypoprothrombinemia. Ten of 41 patients developed an increased prothrombin time, three with a hemorrhagic episode. Serum transport proteins and serum carotene were measured in 18 patients, six of whom developed hypoprothrombinemia. Low serum prealbumin and low serum carotene levels were associated with the development of hypoprothrombinemia. Patients with cancer are especially predisposed to the development of antibiotic-associated hypoprothrombinemia. This is probably a result of protein-calorie malnutrition and low vitamin K stores.

(Arch Intern Med 1986;146:1397-1399)

×